Sinovac Biotech LtdSVA

Sinovac Biotech Ltd. finished 2025 with revenue of $386.0m, a net operating loss of $490.1m, and a headline EPS of minus $0.83, all per the company’s 20-F filed on 5 June 2026. The filing shows total assets of $8.54bn against liabilities of $2.15bn, netting equity of $4.44bn, but the cash story is stranger than the headline numbers: cash and equivalents were $488.2m while short-term investments sat at $5.48bn, a ratio that either signals fortress liquidity or a board that still thinks 2021 cash is going to compound indefinitely. Net cash used in operating activities clocked $512.2m, which is the kind of burn that makes you check whether the inventory line is inflating on purpose or by accident.

Sinovac’s public pitch centres on a “portfolio” of vaccines and adjuvants, but the evidence trail stops at the product pages on the company’s Chinese-language site and a handful of generic images-no actual sales, approvals, or customer counts are disclosed in the filings. The international business page promises global reach without naming countries, customers, or contract values, so the market is left guessing whether the $386m revenue is mostly domestic, export, or grant-funded. The filings do confirm that Sinovac operates through subsidiaries in the PRC and via financing arrangements that require minority-shareholder approval for additional capital calls, which reads less like a growth story and more like a governance footnote.

R&D outlay was $216.2m for 2025, while capex was $48.9m-numbers that sit in stark contrast to the $5.48bn parked in short-term investments and the $512.2m operating cash burn. The inventory line rose by $23.0m to $94.3m, which could be seasonal build, pipeline stockpiling, or simply unsold stock waiting for orders that haven’t arrived. The diluted share count was 71.9m shares, leaving little room for stealth dilution unless the board decides to monetise the investment portfolio without selling a single vial.

Sinovac’s 6-K sequence this year-filed on 21 May, 29 May, 5 June, 15 June, and 15 July 2026-repeats the same pattern: disclosure of intercompany loans capped by registered capital, approval gates for extra injections, and generic updates on product pipelines without concrete sales, approvals, or customer metrics. The SEC’s companyfacts endpoint confirms the headline figures but offers no new disclosure beyond the 20-F, so the market’s view of Sinovac’s trajectory remains constrained by what the company chooses to reveal rather than what it actually sells.

There is The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. What we do know is that the company’s short-term investments dwarf its cash, its operating cash burn exceeds revenue, and its primary filings cycle through governance footnotes rather than customer receipts.

The product rail on Sinovac’s official site shows generic vaccine images and marketing copy without dates, volumes, or third-party verifications, so the reader is left to trust either the visuals or the footnotes-neither of which disclose sales, approvals, or supply contracts. Until the filings or product pages include named customers, contract values, or regulatory approvals with dates, the revenue line of $386.0m remains an assertion rather than an evidence trail.